Ozempic (semaglutide) is a once-weekly GLP-1 receptor agonist that has transformed type 2 diabetes and obesity treatment. Its unprecedented efficacy in glucose control and weight loss has made it one of the fastest-growing drugs in history.
Ozempic mimics GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Achieves A1c reductions of 1.5-2.0% and weight loss of 15-20%.
Annual revenue trajectory
Revenue of competing drugs in the same class
4 indications
All approved therapeutic uses
Ozempic is the market leader in GLP-1 agonists for diabetes with ~50% share. Combined with Wegovy, Novo Nordisk dominates the GLP-1 market. Supply constraints limit further growth.
Ozempic + Wegovy projected to exceed $25B by 2028. Novo expanding manufacturing ($6B+ investment) and exploring new indications (MASH, Alzheimer’s). Competition from Lilly’s Mounjaro/Zepbound intensifying.
| Drug | Company | Revenue |
|---|---|---|
| Mounjaro (tirzepatide) | Eli Lilly | $5.2B |
| Trulicity (dulaglutide) | Eli Lilly | $7.4B |
| Rybelsus (oral semaglutide) | Novo Nordisk | $1.5B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.